inositol has been researched along with ao 128 in 194 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (11.86) | 18.2507 |
| 2000's | 65 (33.51) | 29.6817 |
| 2010's | 94 (48.45) | 24.3611 |
| 2020's | 12 (6.19) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Azukari, K; Kondo, M; Yoshida, T; Yoshioka, K | 1 |
| Akiyoshi, M; Fujitani, S; Ikenoue, T; Kondo, N; Maki, T; Okazaki, K; Tsuchiya, Y | 1 |
| Ashida, K; Azukari, K; Kasamatsu, Y; Kondo, M; Yokoo, S; Yoshida, T; Yoshioka, K | 1 |
| Emoto, M; Inaba, M; Ishimura, E; Kawagishi, T; Morii, H; Nishizawa, Y; Okuno, Y; Tanaka, S; Taniwaki, H | 1 |
| Ehrlich, A; Fuder, H; Kleist, P; Lücker, PW; Suzuki, Y; Timmer, W; Wetzelsberger, N | 1 |
| Birkel, M; Ehrlich, A; Emeklibas, S; Fuder, H; Kleist, P; Lücker, PW; Maslak, W; Stridde, E; Wetzelsberger, N; Wieckhorst, G | 1 |
| Sakamoto, N; Uno, T | 1 |
| Inoue, I; Ishii, J | 1 |
| Hara, T; Hotta, N | 1 |
| Iijima, T | 2 |
| Kitaoka, H | 2 |
| Iwamoto, Y | 1 |
| Akazawa, S; Matsumoto, K; Miyake, S; Tominaga, Y; Ueki, Y; Yamaguchi, Y; Yano, M | 1 |
| Kogure, A; Kondo, M; Sakane, N; Yoshida, T | 1 |
| Fukushige, J; Hara, T; Ihara, K; Kuromaru, R; Ryu, A | 1 |
| Yokoo, S; Yoshida, T; Yoshioka, K | 1 |
| Eckl, KM; Hucke, HP; Kleist, P; Kurowski, M; Möller, M; Römer, A; Suzuki, Y; Thomsen, T | 1 |
| Bando, Y; Fujisawa, M; Tanaka, N; Toya, D; Ushiogi, Y | 1 |
| Fujimoto, S; Ikeda, H; Ishida, H; Kajikawa, M; Kato, S; Mizuno, N; Mukai, E; Nishimura, M; Odaka, H; Seino, Y; Yamada, Y | 1 |
| Mooradian, AD; Thurman, JE | 1 |
| Hiai, H; Ihara, Y; Ikeda, H; Odaka, H; Seino, Y; Tanaka, T; Toyokuni, S; Uchida, K; Yamada, Y | 1 |
| Fujimura, Y; Kameda, T; Kusumoto, M; Mashimo, K; Shibakawa, M; Takeda, K; Tatami, R; Ueno, K | 1 |
| Abe, T; Hayakawa, T; Nomura, G; Yoneshima, M | 1 |
| Ikeda, H; Koyama, M; Mizukami, H; Odaka, H; Sakuraba, H; Wada, R; Yagihashi, S | 1 |
| Komiya, I; Taira, M; Taira, T; Takasu, N; Tanaka, H | 1 |
| Kobayashi, K; Nagai, Y; Nohara, E; Takamura, T; Yamashita, H | 1 |
| Abe, T; Hayakawa, T; Nagai, Y; Nomura, G | 1 |
| Kobayashi, T; Murase, T; Nakanishi, K; Oki, Y; Okubo, M; Tanaka, S | 1 |
| Arima, T; Harada, K; Kawakami, S; Miyazaki, H; Miyazono, H; Oketani, M | 1 |
| Hirose, T; Kasayama, S; Kouhara, H; Miyashita, Y; Sumitani, S; Takagi, M | 1 |
| Ploybutr, S; Tunlakit, M; Vichayanrat, A; Watanakejorn, P | 1 |
| Hiji, Y; Imoto, T; Luo, H | 1 |
| Hayashi, M; Kawachi, S; Kokubo, Y; Nakashima, K; Ozeki, S; Sasaki, A; Sato, M; Takami, K; Takami, R; Takeda, N; Yamada, A; Yasuda, K | 1 |
| Hizawa, K; Matsumoto, T; Nakamura, S; Nakamura, U; Watanabe, K; Yanaru, R; Yoshimura, R; Yoshinari, M | 1 |
| Odaka, H | 1 |
| Ishida, H; Katahira, H | 1 |
| Kawamori, R; Watanabe, K | 1 |
| Kawamori, R; Kitahara, Y; Mine, T; Miura, K; Okano, A | 1 |
| Abe, Y; Matsumoto, K; Miyake, S; Sera, Y; Tominaga, T; Ueki, Y | 1 |
| Adachi, T; Hosokawa, M; Nagashima, K; Odaka, H; Seino, Y; Shihara, N; Shimowada, K; Suzuki, N; Tamon, A; Tsuda, K; Uno, M; Yasuda, K | 1 |
| Scheen, AJ | 2 |
| Yamada, K | 1 |
| Kitahara, Y; Miura, K; Mori, Y; Tajima, N | 1 |
| Ishida, H; Kadowaki, T; Kawamori, R | 1 |
| Ding, LS; Ishurd, O; Pan, YJ; Sun, CR; Zhang, H | 1 |
| Kawagoe, Y; Koide, H; Matsuda, T; Nakamura, T; Ogawa, H; Sekizuka, K; Takahashi, Y | 1 |
| Hayashi, Y; Inoue, K; Kato, T; Yuasa, H | 1 |
| Adisakwattana, S; Kalampakorn, K; Ngamrojanavanich, N; Roengsumran, S; Tiravanit, W; Yibchok-Anun, S | 1 |
| Hatano, M; Hayaishi-Okano, R; Hori, M; Kajimoto, Y; Katakami, N; Kosugi, K; Matsuhisa, M; Yamasaki, Y | 1 |
| Fujisawa, T; Ikegami, H; Inoue, K; Kawabata, Y; Ogihara, T | 1 |
| Nakamura, J | 1 |
| Akkermans, RP; Lucassen, PL; Rutten, GE; Van de Laar, FA; Van de Lisdonk, EH; Van Weel, C | 1 |
| Itoh, Y; Kitahara, Y; Miura, K; Mori, Y; Tajima, N | 1 |
| Nakasute, K; Nishikawa, T; Saito, M; Tanaka, M; Tanikawa, A | 1 |
| Matsumura, N; Nakano, H; Oba, K; Ouchi, M; Suzuki, K; Suzuki, T | 1 |
| Chen, X; Shen, Y; Zheng, Y | 1 |
| Haruta, Y; Hisamoto, A; Matsuo, K; Mizushima, T; Sato, K; Tanimoto, M; Tanimoto, Y | 1 |
| Mori, M; Oh-I, S; Ohtani, KI; Okada, S; Shimizu, H; Tsuchiya, T | 1 |
| Asano, Y; Fujita, M; Hori, M; Kim, J; Kitakaze, M; Liao, Y; Minamino, T; Shintani, Y; Takashima, S; Zhao, H | 1 |
| Hirose, T; Kawamori, R; Kawasumi, M; Kurebayashi, S; Tanaka, Y; Watada, H | 1 |
| Komai, K; Maruta, T; Takamori, M; Yamada, M | 1 |
| Aizawa-Abe, M; Kuzuya, H; Ogawa, Y; Satoh, N; Shimatsu, A; Suganami, T; Yamada, K | 1 |
| Ryu, JK; Woo, JS | 1 |
| Asakura, M; Asanuma, H; Hashimura, K; Kanzaki, H; Kim, J; Kitakaze, M; Kokubo, Y; Komamura, K; Nakatani, S; Tomoike, H | 1 |
| Clark, R; Inoue, T; Nagakura, T; Saeki, T; Sato, Y; Takenaka, O; Tanaka, I; Yamazaki, K; Yasuda, N | 1 |
| Aso, Y; Inukai, T; Matsumoto, S; Matsutomo, R; Suetsugu, M; Takebayashi, K; Wakabayashi, S; Yamamoto, R | 1 |
| Abe, M; Kaizu, K; Kikuchi, F; Matsumoto, K | 1 |
| Kasuga, M; Sakaguchi, K | 1 |
| Kaneto, H; Kasami, R; Kawashima, S; Kuroda, A; Matsuhisa, M; Matsuoka, TA; Sakamoto, K; Shiraiwa, T; Yamamoto, K; Yamasaki, Y; Yasuda, T | 1 |
| Mori, M; Negishi, M; Proks, P; Shimomura, K; Shimomura, Y | 1 |
| Cheng, HM; Shing, TK | 1 |
| Fujii, H; Fukui, H; Kawaratani, H; Mitoro, A; Moriya, K; Shioyama, E; Shirai, Y; Toyohara, M; Tsujimoto, T; Yamao, J | 1 |
| Feng, Y; Hirasawa, Y; Kyuki, K; Matsui, Y; Nagamatsu, T; Ohtsu, S; Sakai, T; Toyoshi, T; Yamane, K | 1 |
| Chino, F; Koh, N; Sakamoto, S | 1 |
| Aoki, K; Ito, Y; Kimura, M; Masuda, K; Muraoka, T; Saito, K; Satoh, K; Shinoda, K; Shirakawa, J; Terauchi, Y; Togashi, Y | 1 |
| Akishita, M; Lisanti, MP; Okamoto, L; Okamoto, T | 1 |
| Prasad, AV; Ramakrishna, K; Raman, NV; Reddy, KR | 1 |
| Hazama, M; Moritoh, Y; Takeuchi, K | 2 |
| Matsui, T; Matsumoto, K; Saito, N; Shimada, M | 1 |
| Iwamoto, Y; Kaku, K; Kashiwagi, A; Kawamori, R; Shimamoto, K; Tajima, N | 2 |
| Domeki, N; Ikeda, S; Kasai, K; Kawagoe, Y; Matsumura, M; Miyashita, Y; Monden, T; Nakatani, Y; Shimizu, H; Yanagi, K | 1 |
| Mühlhauser, I | 1 |
| Shen, L; Sun, X; Yao, L | 1 |
| Dugi, K; Hayashi, N; Horie, Y; Takeuchi, M | 1 |
| Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K | 1 |
| Aoyama, T; Fujiwara, H; Fujiwara, T; Iwasa, M; Kawamura, I; Kobayashi, H; Minatoguchi, S; Nishigaki, K; Shiraki, T; Sumi, S; Takemura, G; Ushikoshi, H; Yamada, Y; Yamaki, T; Yasuda, S | 1 |
| Hu, X; Qu, Q; Sun, Y; Wang, C; Wang, G; Wang, Y; Wen, Q; Yang, G | 1 |
| Kawamori, R | 2 |
| Daida, H; Fukao, K; Fukushima, Y; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miida, T; Miyazaki, T; Ohmura, H; Ohsaka, H; Shimada, K; Sumiyoshi, K | 1 |
| Amatruda, JM; Arjona Ferreira, JC; Iwamoto, Y; Kadowaki, T; Nishii, M; Nonaka, K; Tajima, N; Taniguchi, T | 1 |
| Iwamoto, Y; Kashiwagi, A; Mimori, N; Suzuki, M; Tachibana, H; Terao, S; Yamada, N | 1 |
| Ikeda, S; Ishii, W; Matsuda, M; Shimojima, Y; Tojo, K; Watanabe, R | 1 |
| An, N; Dai, XM; Li, HY; Wu, JM; Zhang, QM | 1 |
| Fujitaka, K; Iwasaka, T; Iwasaki, M; Jo, F; Jo, H; Nishikawa, M; Nomura, E; Otani, H | 1 |
| Fujita, H; Hosoba, M; Morii, T; Narita, T; Sato, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Fujita, T; Hirayama, M; Hiroi, S; Kaku, K; Seino, Y | 1 |
| Araki, E; Dugi, KA; Gong, Y; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; von Eynatten, M; Watada, H; Woerle, HJ | 1 |
| Kataoka, Y; Kimura, K; Kosuge, M; Miyamoto, Y; Miyazaki, S; Sase, K; Yasuda, S; Yoshimasa, Y | 2 |
| Masuzaki, H; Sata, M; Shimabukuro, M | 1 |
| Schnell, O; Standl, E | 1 |
| Fujii, M; Ichikawa, M; Imagawa, M; Inaba, S; Kimura, T; Konoshita, T; Miyamori, I; Sato, S; Suzuki, J; Takahashi, S; Zenimaru, Y | 1 |
| An, J; Bennet, D; Kim, S; Marimuthu, M | 1 |
| Inoue, M | 1 |
| Araki, E; Dugi, K; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; Thiemann, S; von Eynatten, M; Watada, H; Woerle, HJ | 1 |
| Cho, KY; Kameda, H; Ono, Y | 1 |
| Ayaori, M; Iizuka, M; Ikewaki, K; Iwakami, N; Komatsu, T; Murakami, T; Nakaya, K; Ogura, M; Sasaki, M; Sato, H; Takase, B; Takiguchi, S; Uto-Kondo, H; Yakushiji, E; Yogo, M | 1 |
| Ando, K; Morimoto, A; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K | 1 |
| Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M | 1 |
| Bin, BH; Cho, EG; Choi, H; Kim, KH; Lee, E; Lee, TR; Seo, J; Yang, SH | 1 |
| Oho, T; Sato, S; Yamaguchi, T; Zulfiqar, M | 1 |
| Kosaka, T; Kuwahara, Y; Nakamura, K; Otsuki, H; Shimomura, F; Tsukamoto, T | 1 |
| Kawata, T; Matsubara, F; Nagai, Y; Nakamura, Y; Ohshige, T; Ohta, A; Sakai, K; Tanaka, Y; Tenjin, A; Terashima, Y; Tsukiyama, S | 1 |
| Cho, KY; Nakamura, A; Nomoto, H; Ono, Y | 1 |
| Chung, JH; Do, HJ; Hwang, JW; Jin, T; Shin, MJ | 1 |
| Choi, DS; Chung, CH; Jang, HC; Kim, DK; Kim, DM; Kim, IJ; Kwon, HS; Lee, HW; Lee, MK; Lee, MY; Lee, SH; Park, TS; Park, YS; Shin, HK | 1 |
| Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K | 1 |
| Chen, F; Luo, C; Xia, Y; Zhang, H | 1 |
| Cheetham, SC; Headland, KR; Jones, RB; Klein, T; Mark, M; Vickers, SP | 1 |
| Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Chen, FJ; Chen, L; Wu, LH; Zhang, XQ; Zhang, Y | 1 |
| Kaku, K | 1 |
| Hashiguchi, C; Kasai, T; Kawamoto, S; Nagaoka, E; Nishi, Y | 1 |
| Ishida, H; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A | 1 |
| Bin, BH; Cho, EG; Joo, YH; Lee, AY; Lee, TR; Shin, SS | 1 |
| Kamoshima, H; Nakamura, A; Nomoto, H; Ono, Y | 1 |
| Fukuda, S; Hirata, K; Ito, H; Kihara, H; Miyoshi, T; Nakamura, K; Oe, H; Shimada, K; Takagi, T; Watanabe, K; Yoshikawa, J; Yunoki, K | 1 |
| Fuchigami, M; Goda, T; Hariya, N; Inoue, S; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Chanda, S; Choudhury, SR; Das, S; Datta, A; Pathak, AN | 1 |
| Ghim, JL; Kim, DH; Kim, EJ; Kim, HS; Oh, M; Shin, JG; Shon, JH; Song, GS | 1 |
| Ding, Y; Fan, JP; Li, RW; Liu, LG; Shen, WB; Zhang, FF; Zhao, YQ | 1 |
| Choi, HK; Ghim, JL; Kim, EJ; Kim, HS; Oh, M; Shin, JG; Shon, JH; Song, GS | 1 |
| Ahn, KJ; Bao, Y; Chen, L; Chuang, LM; Gao, F; Ji, Q; Jia, W; Li, P; Pang, C; Tu, Y; Xiao, X; Yang, J | 1 |
| Nagai, Y | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Fukuda, S; Hirata, K; Ito, H; Kihara, H; Miyoshi, T; Nakamura, K; Oe, H; Shimada, K; Takagi, T; Yoshikawa, J | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Baik, SH; Cha, BS; Jang, HC; Lee, IK; Lee, KW; Park, TS; Son, JW; Sung, YA; Woo, JT; Yoo, SJ; Yoon, KH | 1 |
| Aoki, C; Aso, Y; Katsura, D; Nishida, M; Sagara, M; Suzuki, K | 1 |
| Phuwapraisirisan, P; Sompornpisut, P; Wacharasindhu, S; Worawalai, W | 1 |
| Ishii, M; Matsumoto, Y; Sekimizu, K | 1 |
| Cho, Y; Do, HJ; Ha, MJ; Hwang, GS; Hwang, YJ; Lee, YS; Shin, MJ; Yi, H | 1 |
| Goto, H; Kohda, Y; Sumiya, K; Tanaka, K; Tomita, T; Yoshida, T | 1 |
| Bai, R; Du, JL; Liu, D; Shi, CH; Wang, H; Wang, L; Wang, YB; Yang, Y; Zhang, XY | 1 |
| Ai, M; Fujimoto, S; Fujitani, Y; Gosho, M; Hirose, T; Hiyoshi, T; Mita, T; Okada, Y; Satoh, H; Takahashi, K; Watada, H | 1 |
| Liu, K; Liu, L; Lu, Y; Ma, P; Sun, L; Wang, M; Wen, Y; Xi, X; Yin, Z | 1 |
| Babu, RJ; Dash, RP; Srinivas, NR | 1 |
| Ihana-Sugiyama, N; Kakei, M; Noda, M; Sugiyama, T; Tsujimoto, T; Yamamoto-Honda, R | 1 |
| Asakura, M; Asanuma, H; Doi, O; Endo, T; Fujino, S; Fujita, M; Fukui, K; Hamasaki, T; Hashimoto, Y; Hayashi, H; Hiasa, Y; Higaki, J; Higashino, Y; Himeno, H; Ikeda, S; Ishikawa, T; Kim, J; Kinoshita, Y; Kitakaze, M; Koba, S; Kohno, T; Maruyama, Y; Mizuno, S; Morii, I; Morita, Y; Murohara, T; Muroya, T; Nagai, Y; Nakahama, M; Nakama, Y; Nunohiro, T; Ohkusa, T; Ohte, N; Sakagami, S; Sata, M; Satake, K; Sawada, R; Shigemasa, T; Shimizu, M; Shiono, T; Suzuki, H; Takase, H; Tamita, K; Tsujimoto, M; Tsukahara, K; Ueda, T; Uzui, H; Yamada, T; Yamaguchi, H; Yamanouchi, T; Yoda, S | 1 |
| Han, K; Ji, F; Li, D; Sun, H; Sun, T; Wu, B; Yang, S; Zhang, G; Zhou, D | 1 |
| Hirai, H; Hiyoshi, T; Inoue, I; Kuribayashi, S; Moriya, C; Ohira, T; Satoh, H; Seino, H; Watada, H | 1 |
| Imaeda, K; Koyama, H; Ohguchi, H; Yagi, T | 1 |
| Anand, RK; Awasthi, S; Kumar, R; Rai, AK; Rai, PK; Tiwari, PK | 1 |
| Akita, E; Chimori, H; Fujitani, Y; Gosho, M; Inoue, I; Kurozumi, A; Mita, T; Okada, Y; Satoh, H; Shiraiwa, T; Watada, H | 1 |
| Inoue, T; Koyama, T; Node, K; Otsuka, Y; Oyama, JI; Sakuma, M; Tanaka, A; Toyoda, S; Yoshida, H | 1 |
| Demitsu, T; Izumi, K; Kakurai, M; Kawase, M; Maki, N; Nishie, W; Shimizu, H; Takazawa, M; Umemoto, N; Yamada, T | 1 |
| Fujimoto, K; Hamamoto, Y; Hamasaki, A; Honjo, S; Shibayama, Y; Yamaguchi, E | 1 |
| Do, HJ; Hwang, GS; Jung, Y; Shin, MJ; Yang, SJ | 1 |
| Kohda, Y; Kudo, K; Tomita, T | 1 |
| Ai, M; Fujimoto, S; Fujitani, Y; Gosho, M; Goto, H; Hirose, T; Hiyoshi, T; Ishii, H; Kuroda, H; Matsubara, T; Mita, T; Nishimura, H; Okada, Y; Satoh, H; Takahashi, K; Watada, H | 1 |
| Dohi, K; Fujimoto, N; Ishida, M; Ito, M; Kumagai, N; Masuda, J; Moriwaki, K; Nakamori, S; Nakamura, M; Sakuma, H; Sato, Y; Sawai, T; Takeuchi, T; Yamada, N | 1 |
| Jedrzejczak, RP; Joachimiak, A; Tan, K; Tesar, C; Wilton, R | 1 |
| Cai, L; Chen, LL; Deng, SP; Lu, YQ; Ma, WY; Ni, YS; Tian, SY; Wang, LN; Xu, GD | 1 |
| Bhansali, A; Bhansali, S; Bhat, K; Kurpad, AV; Parthan, G; Walia, R | 1 |
| Kim, EJ; Kim, EY; Kim, HS; Oh, M; Shin, JG; Song, GS | 1 |
| Aiba, S; Imai, J; Katagiri, H; Kikuchi, K; Kohata, M; Kurosawa, S; Nakajima, T; Satake, C; Sawada, S; Takahashi, K; Takeda, K; Tsuchiya, S | 1 |
| Akkermans, RP; De Grauw, WJ; Lucassen, PL; Moelands, SV; Van de Laar, FA | 1 |
| Baik, SH; Cha, BS; Choi, SH; Jeong, IK; Kim, DM; Kim, IJ; Kim, SR; Kim, YS; Lee, IK; Lee, KW; Lee, MK; Min, KW; Oh, TJ; Park, JH; Park, JY; Park, SW; Park, TS; Son, HS; Song, YD; Yoon, KH; Yu, JM | 1 |
| Asai, Y; Imai, J; Izumi, T; Kaneko, K; Katagiri, H; Satake, C; Sawada, S; Tanaka, M; Yamada, T; Yamamoto, J | 1 |
| Bai, R; Du, J; Liu, D; Shi, C; Wang, H; Wang, Y; Zhang, R; Zhang, X | 1 |
| Hakamata, A; Inui, N; Kamiya, C; Kashiwagura, Y; Namiki, N; Odagiri, K; Sotoyama, M; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Seok, H; Sohn, TS | 1 |
| Choi, SH; Oh, TJ | 1 |
| Fukui, M; Hasegawa, G; Hirata, A; Kadono, M; Nakajima, H; Okada, H; Okada, Y; Oyamada, H; Tanaka, M; Yamane, T | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Ibuka, T; Kato, J; Kubota, M; Mizutani, T; Sakai, H; Shimizu, M; Shirakami, Y | 1 |
| Cha, DH; Jeong, TC; Kang, MJ; Kim, GH; Kim, JH; Nepal, MR | 1 |
| Akagi, S; Ejiri, K; Fuke, S; Hata, Y; Ito, H; Kawai, Y; Kihara, H; Minagawa, T; Miyoshi, T; Nagano, T; Nakamura, K; Nakamura, Y; Nanba, S; Nishii, N; Sakuragi, S; Takaishi, A; Toda, H; Yoshikawa, M | 1 |
| Ashraf, GM; Bhadada, S; Chavda, V; Patel, S; Shah, P | 1 |
| Bhadada, S; Chavda, V; Patel, SS; Shah, P | 1 |
| Alssema, M; Blaak, EE; Dekker, JM; Denise Robertson, M; Dussort, P; Egli, L; Ruijgrok, C; Vinoy, S | 1 |
| Kaur, N; Kaur, P; Kumar, V; Nayak, SK; Sahu, SK; Wadhwa, P | 1 |
| Durga Priyadharshini, R; Elango, KP; Ponkarpagam, S; Vennila, KN | 1 |
| Bae, J; Cha, BS; Kang, ES; Lee, BW; Lee, JY; Lee, M; Lee, YH; Shin, E | 1 |
| Akagi, S; Ejiri, K; Fuke, S; Hata, Y; Ito, H; Kawai, Y; Kihara, H; Minagawa, T; Miyoshi, T; Nagano, T; Nakamura, K; Nakamura, Y; Namba, S; Nishii, N; Sakuragi, S; Takaishi, A; Toda, H; Yoshikawa, M | 1 |
| Cao, H; Chen, L; Feng, C; Fu, Y; Gao, X; Huan, Y; Ji, W; Lei, L; Li, C; Li, P; Liu, Q; Liu, S; Shen, Z; Zhai, J; Zhang, L | 1 |
29 review(s) available for inositol and ao 128
| Article | Year |
|---|---|
[Oral hypoglycemic agents--overview].
Topics: Acarbose; Administration, Oral; Biguanides; Chromans; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Measures to meet the side effects of the orally administered antihyperglycemic drugs].
Topics: Acarbose; Administration, Oral; Animals; Biguanides; Cardiovascular System; Chromans; Drug Interactions; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Inositol; Insulin Resistance; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Voglibose].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus; Diet, Diabetic; Dietary Carbohydrates; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Patient Selection | 1997 |
[Combination therapy with sulfonylurea and alpha-glucosidase inhibitor].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Protein Precursors; Sulfonylurea Compounds | 1997 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Management of postprandial hyperglycemia].
Topics: Acarbose; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise Therapy; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Insulin Resistance; Postprandial Period; Sulfonylurea Compounds; Trisaccharides | 1997 |
Drug therapy of postprandial hyperglycaemia.
Topics: 1-Deoxynojirimycin; Acarbose; Amyloid; Carbamates; Diabetes Mellitus; Enzyme Inhibitors; Glucosamine; Glyburide; Humans; Hyperglycemia; Hypoglycemic Agents; Imino Pyranoses; Inositol; Insulin; Insulin Lispro; Islet Amyloid Polypeptide; Piperidines; Postprandial Period; Trisaccharides | 1999 |
[alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].
Topics: Acarbose; Animals; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Inositol; Obesity; Postprandial Period | 2002 |
[Indication and side effect of alpha glucosidase inhibitor].
Topics: Acarbose; Chemical and Drug Induced Liver Injury; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperammonemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Patient Selection | 2002 |
[Combination therapy with insulin and alpha-glucosidase inhibitor].
Topics: Acarbose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Postprandial Period | 2002 |
[Sulfonylurea and alpha-glucosidase inhibitor].
Topics: Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin Resistance; Insulin Secretion; Sulfonylurea Compounds | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2003 |
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Topics: Acarbose; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Inositol; Insulin Resistance; Nateglinide; Obesity; Phenylalanine; Postprandial Period | 2003 |
[Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Topics: Animals; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Insulin Secretion; Intestinal Absorption; Male; Middle Aged; Randomized Controlled Trials as Topic | 2005 |
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2005 |
Additive contribution of multiple factors in the development of pneumatosis intestinalis: a case report and review of the literature.
Topics: Adrenal Cortex Hormones; Dermatomyositis; Female; Humans; Hypoglycemic Agents; Inositol; Middle Aged; Oxygen Inhalation Therapy; Pneumatosis Cystoides Intestinalis | 2007 |
Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors.
Topics: Biochemistry; Carbohydrate Sequence; Cyclohexanols; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Inositol; Molecular Sequence Data | 2006 |
[Adverse effects of alpha-glucosidase inhibitors].
Topics: 1-Deoxynojirimycin; Acarbose; Digestive System Diseases; Drug Interactions; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperammonemia; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Inositol | 2007 |
Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: a case report and review of the literature.
Topics: Aged; Diabetes Mellitus; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Male; Pneumatosis Cystoides Intestinalis | 2008 |
Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.
Topics: Diabetes Complications; Drug Therapy, Combination; Glucocorticoids; Humans; Hypoglycemic Agents; Inositol; Lupus Vasculitis, Central Nervous System; Male; Middle Aged; Pneumatosis Cystoides Intestinalis; Prednisolone; Sulfonylurea Compounds; Tomography, X-Ray Computed | 2011 |
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol | 2012 |
Efficacy of voglibose in type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Inositol; Insulin; Practice Guidelines as Topic; Treatment Outcome | 2014 |
Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Developing Countries; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Feeding Behavior; Glucosides; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Nanotechnology; Prevalence; Risk Reduction Behavior; Stem Cell Transplantation; Urbanization | 2014 |
[Effect of Food Thickeners on the Disintegration, Dissolution, and Drug Activity of Rapid Oral-disintegrating Tablets].
Topics: Administration, Oral; Food Additives; Food-Drug Interactions; Humans; Inositol; Magnesium Oxide; Solubility; Tablets | 2018 |
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Topics: Acarbose; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diet; Exercise; Fasting; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Humans; Incidence; Inositol; Metformin; Prediabetic State; Randomized Controlled Trials as Topic | 2018 |
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Metformin; Prediabetic State | 2019 |
Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus; Glucose; Glycoside Hydrolase Inhibitors; Humans; Inositol; Insulin; Postprandial Period | 2021 |
Alpha-amylase as molecular target for treatment of diabetes mellitus: A comprehensive review.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Amylases; Benzofurans; Blood Glucose; Diabetes Mellitus; Drug Discovery; Flavonoids; Glycoside Hydrolase Inhibitors; Humans; Hydrazones; Hypoglycemic Agents; Indoles; Inositol; Oxadiazoles; Structure-Activity Relationship | 2021 |
73 trial(s) available for inositol and ao 128
| Article | Year |
|---|---|
Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.
Topics: Acetaminophen; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Gastric Emptying; Glycoside Hydrolase Inhibitors; Humans; Inositol; Insulin; Male; Metabolic Clearance Rate; Middle Aged; Postprandial Period; Regression Analysis | 1997 |
Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.
Topics: Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Glyburide; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Male | 1997 |
The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin.
Topics: Adult; Anticoagulants; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Prothrombin Time; Reference Values; Warfarin | 1997 |
Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Inositol; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Triglycerides | 1998 |
Lack of kinetic interaction between digoxin and voglibose.
Topics: Adult; Cross-Over Studies; Digoxin; Drug Interactions; Enzyme Inhibitors; Humans; Inositol; Male; Middle Aged | 1999 |
Voglibose administration before the evening meal improves nocturnal hypoglycemia in insulin-dependent diabetic patients with intensive insulin therapy.
Topics: Adolescent; Adult; Aged; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Drug Administration Schedule; Eating; Enzyme Inhibitors; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged | 2000 |
Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Sulfonylurea Compounds; Time Factors | 2001 |
Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.
Topics: Acarbose; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Food; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged | 2002 |
Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Adult; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Energy Intake; Fasting; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Triglycerides | 2002 |
Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Middle Aged; Sulfonylurea Compounds; Survival Analysis; Time Factors | 2002 |
Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.
Topics: Albuminuria; Blood Pressure; Blood Urea Nitrogen; Carotid Arteries; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Pioglitazone; Protein Precursors; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness.
Topics: Analysis of Variance; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Patient Selection; Regression Analysis; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study.
Topics: Adiponectin; Administration, Oral; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Leptin; Male; Middle Aged; Pioglitazone; Plasminogen Activator Inhibitor 1; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2006 |
Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
Topics: Aged; alpha-Glucosidases; Appetite; Body Weight; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrointestinal Tract; Glycated Hemoglobin; Humans; Hypoglycemia; Inositol; Lipids; Liver Function Tests; Male; Middle Aged; Nateglinide; Phenylalanine; Treatment Outcome | 2006 |
Voglibose inhibits postprandial hypotension in neurologic disorders and elderly people.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Blood Glucose; Diabetes Mellitus; Female; Glycoside Hydrolase Inhibitors; Humans; Hypotension; Inositol; Insulin; Male; Middle Aged; Multiple System Atrophy; Neurotensin; Postprandial Period | 2006 |
An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Female; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inositol; Intercellular Adhesion Molecule-1; Japan; Male; Middle Aged; Obesity; Oxidative Stress; Single-Blind Method; Solubility | 2006 |
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Male; Molecular Weight; Pioglitazone; Plasminogen Activator Inhibitor 1; Thiazolidinediones; Treatment Outcome | 2007 |
Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
Topics: Aged; Asian People; Blood Glucose; Case-Control Studies; Demography; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Japan; Lipids; Male; Pioglitazone; Renal Dialysis; Thiazolidinediones | 2007 |
Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain | 2008 |
Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet.
Topics: Administration, Oral; Aged; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Male; Medication Adherence; Middle Aged; Tablets | 2008 |
Comparison of pre- versus post-meal administration of voglibose in men with or without impaired glucose tolerance.
Topics: Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Drug Administration Schedule; Eating; Glucose Intolerance; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Postprandial Period | 2009 |
Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2008 |
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
Topics: Administration, Oral; Analysis of Variance; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incidence; Inositol; Japan; Kaplan-Meier Estimate; Life Style; Male; Middle Aged; Prevalence; Proportional Hazards Models; Risk Assessment; Risk Reduction Behavior; Severity of Illness Index | 2009 |
Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.
Topics: Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Humans; Hypoglycemic Agents; Inositol; Placebos; Prospective Studies; Research Design; Sample Size | 2009 |
[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance].
Topics: Asian People; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Enzyme Inhibitors; Female; Glucose Intolerance; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Life Style; Male; Middle Aged; Risk | 2009 |
Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Isoindoles; Male; Renal Dialysis; Treatment Outcome | 2010 |
[Voglibose for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Prediabetic State | 2010 |
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic p
Topics: 1-Deoxynojirimycin; Aged; Coronary Artery Disease; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Glucose; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Inositol; Lipid Metabolism; Male; Middle Aged; Treatment Outcome | 2010 |
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Topics: Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.
Topics: Adamantane; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin | 2010 |
Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Metabolic Syndrome; Metabolome; Obesity; Pioglitazone; Thiazolidinediones | 2011 |
[Evidence demonstrating the effect of voglibose for the prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese subjects with inpaired glucose tolerance].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Inositol; Male; Metabolic Syndrome; Middle Aged | 2011 |
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Inositol; Male; Middle Aged; Obesity; Postprandial Period | 2012 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Piperidines; Time Factors; Uracil | 2011 |
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Inositol; Japan; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2012 |
Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients.
Topics: Aged; Coronary Artery Disease; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Female; Glycemic Index; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Nateglinide; Phenylalanine | 2012 |
Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Topics: 1-Deoxynojirimycin; Apolipoprotein A-I; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Lispro; Lipids; Lipoproteins, HDL; Male; Middle Aged; Postprandial Period; Treatment Outcome; Triglycerides | 2012 |
Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucagon; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Male; Middle Aged | 2012 |
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Time Factors | 2013 |
Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Isoindoles; Japan; Lipids; Male; Middle Aged; Postprandial Period; Treatment Outcome | 2013 |
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol; Japan; Linear Models; Male; Middle Aged; Piperidines; Prospective Studies; Pyrazines; Regional Blood Flow; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Uracil; Vasodilation | 2013 |
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inositol; Kidney Failure, Chronic; Male; Middle Aged; Nitriles; Prospective Studies; Pyrazoles; Pyrrolidines; Renal Dialysis; Serum Albumin; Thiazolidines; Vildagliptin | 2014 |
Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes.
Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Male; Middle Aged; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2013 |
Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Metformin; Middle Aged; Prospective Studies | 2014 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Piperidines; Treatment Outcome; Uracil | 2014 |
Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
Topics: Acarbose; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Isoindoles; Male; Middle Aged; Prospective Studies; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2014 |
Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose c
Topics: Aged; Blood Glucose; Breakfast; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Insulin Secretion; Isoindoles; Lunch; Male; Meals; Middle Aged; Postprandial Period | 2014 |
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult | 2014 |
Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Asian People; Blood Glucose; Cardiovascular Diseases; Chemokine CCL2; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Prospective Studies; Risk Factors; Time Factors | 2014 |
Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.
Topics: Adult; Cross-Over Studies; Drug Interactions; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged | 2014 |
Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin.
Topics: Adult; Cross-Over Studies; Drug Combinations; Humans; Hypoglycemic Agents; Inositol; Metformin; Middle Aged; Therapeutic Equivalency; Young Adult | 2015 |
Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily pre
Topics: Acarbose; Aged; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Inositol; Insulin Glargine; Insulin Lispro; Male; Metformin; Middle Aged; Republic of Korea; Taiwan; Treatment Outcome | 2015 |
Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Japan; Lipoproteins, LDL; Male; Pilot Projects; Sulfonylurea Compounds | 2016 |
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diastole; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Middle Aged; Sitagliptin Phosphate; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Insulin Glargine; Isoindoles; Male; Middle Aged; Prospective Studies | 2015 |
[Comparison of therapeutic effects between sitagliptin and voglibose both combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hyperinsulinism; Inositol; Insulin Infusion Systems; Insulins; Postprandial Period; Sitagliptin Phosphate | 2016 |
Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Inositol; Japan; Linagliptin; Male; Middle Aged; Postprandial Period; Retrospective Studies; Time Factors; Young Adult | 2016 |
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin, Long-Acting; Isoindoles; Linagliptin; Male; Metformin; Middle Aged; Postprandial Period | 2017 |
Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Topics: Aged; Cardiovascular Diseases; Female; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Secondary Prevention; Treatment Outcome | 2017 |
Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Monitoring; Female; Humans; Hypoglycemic Agents; Inositol; Japan; Linagliptin; Male; Middle Aged | 2017 |
Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Lipids; Male; Middle Aged; Postprandial Period; Treatment Outcome | 2018 |
Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Inositol; Isoindoles; Male; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Treatment Outcome | 2018 |
Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
Topics: Activities of Daily Living; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Male; Middle Aged; Quality of Life; Treatment Outcome | 2018 |
Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period | 2018 |
Pharmacodynamic effects of voglibose administered alone, administered with metformin, and administered with metformin in a fixed-dose combination in healthy Korean subjects
.
Topics: Adult; Area Under Curve; Asian People; Blood Glucose; Cross-Over Studies; Drug Combinations; Enzyme Inhibitors; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Metformin; Tablets; Young Adult | 2018 |
Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycemic Index; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome; Young Adult | 2019 |
Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Japan; Piperidines | 2020 |
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Heart Failure; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Stroke Volume | 2020 |
Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.
Topics: Adiponectin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Inositol; Malondialdehyde; Sodium; Sorbitol | 2022 |
92 other study(ies) available for inositol and ao 128
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of alpha-glucosidase inhibitor.
Topics: Biomarkers; Deoxyglucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Inositol; Isomerism; Male; Middle Aged | 1997 |
Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Glucose; Glyburide; Hypoglycemic Agents; Inositol; Insulin; Male; Nateglinide; Phenylalanine; Postprandial Period; Rats; Rats, Wistar; Sucrose | 1997 |
The efficacy of voglibose on daily glycemic excursions assessed by the "J"-index in non-insulin dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged | 1997 |
Different effects of acarbose and voglibose on serum 1,5-anhydroglucitol concentrations.
Topics: Acarbose; Aged; Deoxyglucose; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Middle Aged; Trisaccharides | 1998 |
Prevention of hypoglycaemia in a patient with type Ib glycogen storage disease by an amylase (alpha-glucosidase) inhibitor.
Topics: Adolescent; Blood Glucose; Glycogen Storage Disease Type I; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Inositol; Male | 1998 |
The efficacy of voglibose on glycemic excursions in non-insulin-treated NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Inositol; Insulin; Insulin Resistance; Insulin Secretion; Treatment Outcome | 1998 |
Voglibose has no effect on the pharmacokinetics of hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Drug Interactions; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hydrochlorothiazide; Inositol; Male | 1998 |
Three diabetic cases of acute dizziness due to initial administration of voglibose.
Topics: Aged; Aged, 80 and over; Cerebral Infarction; Cerebrovascular Circulation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dizziness; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Nausea; Vomiting | 1998 |
Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fasting; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Insulin; Insulin Secretion; Islets of Langerhans; Male; Pioglitazone; Rats; Rats, Mutant Strains; Rats, Wistar; Thiazoles; Thiazolidinediones; Triglycerides | 1998 |
Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Blood Glucose; Deoxyguanosine; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Hyperglycemia; Immunohistochemistry; Inositol; Insulin; Islets of Langerhans; Oxidative Stress; Proteins; Rats; Rats, Inbred Strains; Solutions; Sucrose | 1999 |
Pneumatosis cystoides intestinalis after treatment with an alpha-glucosidase inhibitor.
Topics: Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Middle Aged; Pneumatosis Cystoides Intestinalis | 1999 |
Inhibition of progressive reduction of islet beta-cell mass in spontaneously diabetic Goto-Kakizaki rats by alpha-glucosidase inhibitor.
Topics: Aging; Animals; Body Weight; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Inositol; Islets of Langerhans; Male; Rats; Rats, Mutant Strains; Rats, Wistar | 2000 |
Ischemic colitis probably induced by refractory constipation after voglibose administration in a patient with total gastrectomy.
Topics: Aged; Colitis, Ischemic; Constipation; Enzyme Inhibitors; Female; Gastrectomy; Glycoside Hydrolase Inhibitors; Humans; Inositol | 2000 |
Are there different effects of acarbose and voglibose on serum levels of digoxin in a diabetic patient with congestive heart failure?
Topics: Acarbose; Aged; Aged, 80 and over; Cardiotonic Agents; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Inositol; Male | 2000 |
Diabetes mellitus secondary to glycogen storage disease type III.
Topics: Age of Onset; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Disease Progression; Enzyme Inhibitors; Glycogen Storage Disease Type III; Glycoside Hydrolase Inhibitors; Humans; Inositol; Insulin; Male; Middle Aged | 2000 |
Hepatic necrosis with cholestasis induced by long-term voglibose administration.
Topics: Aged; Cholestasis; Enzyme Inhibitors; Female; Humans; Inositol; Liver; Necrosis; Time Factors | 2001 |
Inhibitory effect of voglibose and gymnemic acid on maltose absorption in vivo.
Topics: Animals; Diabetes Mellitus; Enzyme Inhibitors; Inositol; Intestine, Small; Male; Maltose; Rats; Rats, Wistar; Saponins; Triterpenes | 2001 |
Regression of pneumatosis cystoides intestinalis after discontinuing of alpha-glucosidase inhibitor administration.
Topics: Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Middle Aged; Pneumatosis Cystoides Intestinalis | 2002 |
Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
Topics: Animals; Blood Glucose; Cyclohexanes; Glyburide; Hypertriglyceridemia; Inositol; Male; Nateglinide; Phenylalanine; Postprandial Period; Rats; Rats, Wistar; Rats, Zucker; Species Specificity | 2002 |
Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats.
Topics: Alkaline Phosphatase; Animals; Blood Glucose; Blotting, Northern; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Disaccharidases; Disease Models, Animal; Eating; Enzyme Inhibitors; Inositol; Insulin; Intestinal Mucosa; Male; Rats; Rats, Wistar; RNA, Messenger | 2003 |
Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
Topics: Animals; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Inhibitors; Fatty Acids, Nonesterified; Hypoglycemic Agents; Inositol; Insulin; Insulin Secretion; Male; Nateglinide; Phenylalanine; Portal Vein; Postprandial Period; Rats; Rats, Inbred OLETF; Secretory Rate; Sucrose | 2004 |
[Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Topics: Administration, Oral; Cardiovascular Diseases; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Indoles; Inositol; Insulin; Insulin Resistance; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Risk Factors; Stimulation, Chemical; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Determination of the structures of four new isomeric cyclitols.
Topics: Carbohydrate Conformation; Inositol; Models, Molecular; Molecular Weight; Stereoisomerism; X-Ray Diffraction | 2004 |
Functional characterization of the carrier-mediated transport system for glycerol in everted sacs of the rat small intestine.
Topics: Alcohols; Animals; Biological Transport, Active; Chloramphenicol; Colon; Drug Carriers; Glycerol; In Vitro Techniques; Inositol; Intestinal Absorption; Intestine, Small; Male; Rats; Rats, Wistar; Sodium; Time Factors | 2004 |
Inhibitory activity of cyanidin-3-rutinoside on alpha-glucosidase.
Topics: alpha-Glucosidases; Anthocyanins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Inositol; Kinetics; Molecular Structure; Yeasts | 2004 |
Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
Topics: Acarbose; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Flatulence; Food; Gastrointestinal Tract; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Inositol; Male; Middle Aged | 2005 |
Suppression of body weight gain preserves acute insulin response to glucose in the portal vein of spontaneously type 2 diabetic rats with visceral obesity.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Immunohistochemistry; Inositol; Insulin; Islets of Langerhans; Obesity; Portal Vein; Prediabetic State; Rats; Rats, Inbred OLETF; Weight Gain | 2005 |
Repeated episodes of paralytic ileus in an elderly diabetic patient treated with voglibose.
Topics: Aged; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Intestinal Pseudo-Obstruction; Male | 2006 |
Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis.
Topics: Diabetes Mellitus; Enzyme Inhibitors; Female; Glucocorticoids; Glucosidases; Humans; Hypoglycemic Agents; Inositol; Lung Diseases, Interstitial; Middle Aged; Pneumatosis Cystoides Intestinalis; Prednisone | 2006 |
Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice.
Topics: Acetophenones; Animals; Blotting, Western; Body Weight; Cells, Cultured; Disease Progression; Echocardiography; Fatty Acids, Nonesterified; Glucose; Glycoside Hydrolase Inhibitors; Heart Failure; Hyperglycemia; Inositol; Insulin; Lung; Male; Mice; Mice, Inbred C57BL; Models, Animal; Myocardium; Myocytes, Cardiac; NADPH Oxidases; Organ Size; Oxidative Stress; Rats; Reverse Transcriptase Polymerase Chain Reaction; Ventricular Dysfunction, Left | 2006 |
Quantitative determination of voglibose in pharmaceutical tablets using high-performance liquid chromatography-fluorescence detection with post-column derivatization and mass spectrometric detection.
Topics: Chromatography, High Pressure Liquid; Fluorescence; Inositol; Mass Spectrometry; Tablets | 2006 |
Abnormal glucose tolerance contributes to the progression of chronic heart failure in patients with dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Chronic Disease; Disease Progression; Echocardiography; Female; Glucose Intolerance; Glucose Tolerance Test; Heart Failure; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Natriuretic Peptide, Brain; Prevalence; Severity of Illness Index | 2006 |
Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Topics: Acarbose; Administration, Oral; Animals; Area Under Curve; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dietary Sucrose; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Food, Formulated; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hyperglycemia; Hypoglycemic Agents; Imidazoles; Injections, Intravenous; Inositol; Insulin; Male; Mice; Mice, Inbred C57BL; Postprandial Period; Pyridazines; Tosyl Compounds | 2007 |
Acute progression of severe insulin edema accompanied by pericardial and pleural effusion in a patient with type 2 diabetes.
Topics: Administration, Oral; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Edema; Humans; Hypoglycemic Agents; Inositol; Insulin, Isophane; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Sulfonylurea Compounds | 2008 |
Intramolecular direct aldol reactions of sugar diketones: syntheses of valiolamine and validoxylamine G.
Topics: Aldehydes; Carbohydrates; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Inositol; Ketones | 2008 |
Involvement of hyperglycemia in deposition of aggregated protein in glomeruli of diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Glucose; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Kidney Glomerulus; Lysine; Male; Mice; Mice, Inbred ICR; Pioglitazone; Serum Albumin; Serum Albumin, Bovine; Thiazolidinediones | 2008 |
Development and validation of LC methods with visible detection using pre-column derivatization and mass detection for the assay of voglibose.
Topics: Chromatography, High Pressure Liquid; Hypoglycemic Agents; Inositol; Practice Guidelines as Topic; Tandem Mass Spectrometry | 2009 |
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Gene Expression; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Time Factors | 2009 |
Alpha-glucosidase inhibition assay in an enzyme-immobilized amino-microplate.
Topics: Acarbose; alpha-Glucosidases; Animals; beta-Alanine; Biocatalysis; Enzyme Inhibitors; Enzyme Stability; Enzymes, Immobilized; Glutaral; Glycoside Hydrolase Inhibitors; Inhibitory Concentration 50; Inositol; Male; Rats; Rats, Sprague-Dawley; Time Factors | 2009 |
Voglibose for prevention of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Inositol; Life Style; Patient Education as Topic; Risk Reduction Behavior | 2009 |
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Topics: Acarbose; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Triglycerides | 2009 |
Voglibose for prevention of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Inositol | 2009 |
Voglibose for prevention of type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol | 2009 |
Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Hypoglycemic Agents; Inositol; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Piperidines; Prediabetic State; RNA-Binding Proteins; Transcription Factors; Uracil | 2010 |
Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits.
Topics: alpha-Glucosidases; Animals; Arginine; Decanoic Acids; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Heart; Hydroxy Acids; Hypoglycemic Agents; Inositol; Male; Myocardial Infarction; Myocardial Ischemia; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphotransferases; Proto-Oncogene Proteins c-akt; Rabbits; Receptors, Glucagon; Reperfusion Injury | 2010 |
Novel reagents for quantitative analysis of valiolamine in biological samples by high-performance liquid chromatography with pre-column UV derivatization.
Topics: Biotechnology; Calibration; Chemistry Techniques, Analytical; Chromatography; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Inositol; Models, Chemical; Nitrobenzenes; Pharmaceutical Preparations; Quality Control; Temperature; Time Factors; Ultraviolet Rays | 2010 |
Development and validation of HPLC-UV-MS method for the control of four anti-diabetic drugs in suspected counterfeit products.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Glucosidases; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet | 2010 |
Intensive glucose lowering in cardiovascular risk management - unsolved questions - .
Topics: Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus; Female; Glycemic Index; Humans; Inositol; Male; Nateglinide; Phenylalanine | 2012 |
Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery.
Topics: Adult; Biocompatible Materials; Cell Line; Delayed-Action Preparations; Fibroblasts; Humans; Hydrogen-Ion Concentration; Inositol; Lactic Acid; Male; Nanoparticles; Nanostructures; Oleic Acid; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quercetin; Skin Absorption; Temperature | 2012 |
Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Aged, 80 and over; alpha-Glucosidases; Enzyme Inhibitors; Female; Gases; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Intestinal Mucosa; Male; Middle Aged; Pneumatosis Cystoides Intestinalis; Predictive Value of Tests; Risk Assessment; Risk Factors | 2012 |
Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Novel inhibitory effect of the antidiabetic drug voglibose on melanogenesis.
Topics: Acarbose; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Inflammation; Inositol; Mannosidases; Melanins; Melanocytes; Microscopy, Electron, Transmission; Monophenol Monooxygenase; Permeability; Polysaccharides; Real-Time Polymerase Chain Reaction; Skin | 2013 |
Oral Fusobacterium nucleatum subsp. polymorphum binds to human salivary α-amylase.
Topics: Acarbose; Bacterial Adhesion; beta-Amylase; Enzymes, Immobilized; Fusobacterium Infections; Fusobacterium nucleatum; Glycoside Hydrolase Inhibitors; Humans; Inositol; Periodontal Diseases; Saliva; Salivary alpha-Amylases | 2013 |
The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Breakfast; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Acids, Nonesterified; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Lunch; Male; Meals; Middle Aged; Postprandial Period; Triglycerides | 2014 |
Voglibose administration regulates body weight and energy intake in high fat-induced obese mice.
Topics: Adiposity; Agouti-Related Protein; Animals; Appetite; Body Weight; Diet, High-Fat; Energy Intake; Gene Expression Regulation; Glucose Transporter Type 4; Hypothalamus; Inositol; Insulin; Insulin Resistance; Insulin-Secreting Cells; Leptin; Liver; Male; Mice; Mice, Obese; Nerve Tissue Proteins; Neuropeptide Y; Organ Specificity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pro-Opiomelanocortin; Receptors, Leptin; Transcription Factors; Triglycerides | 2014 |
Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: Insight from the DIANA study.
Topics: Blood Glucose; Coronary Angiography; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Life Style; Male; Middle Aged; Nateglinide; Phenylalanine; Plaque, Atherosclerotic; Prospective Studies; Risk Factors; Ultrasonography, Interventional | 2014 |
A new method for evaluating the dissolution of orodispersible films.
Topics: Administration, Oral; Chemistry, Pharmaceutical; China; Drug Delivery Systems; Hypoglycemic Agents; Inositol; Mouth; Pharmacopoeias as Topic; Reproducibility of Results; Solubility | 2015 |
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Hypoglycemic Agents; Inositol; Linagliptin; Male; Peptides; Purines; Quinazolines; Rats; Rats, Zucker; Treatment Outcome; Venoms | 2014 |
[Quantitative determination of voglibose contents in its tablets with high-performance liquid chromatography-mass spectrometry].
Topics: Chromatography, High Pressure Liquid; Inositol; Mass Spectrometry; Tablets | 2014 |
Influence of an antidiabetic drug on biomechanical and histological parameters around implants in type 2 diabetic rats.
Topics: Alveolar Process; Animals; Biomechanical Phenomena; Dental Implants; Dental Stress Analysis; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Inositol; Male; Mice, Inbred Strains; Osteogenesis; Rats; Rats, Wistar | 2014 |
Novel inhibitory effect of N-(2-hydroxycyclohexyl)valiolamine on melanin production in a human skin model.
Topics: Cells, Cultured; Cyclohexanols; Humans; Inositol; Melanins; Melanocytes; Monophenol Monooxygenase | 2014 |
Structural identification of 4-benzyl-voglibose hydrochloride monohydrate using NMR and single-crystal X-ray diffraction methods.
Topics: Crystallography, X-Ray; Inositol; Magnetic Resonance Spectroscopy | 2015 |
[Fixed-dose combination].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones; Uracil | 2015 |
Postprandial Reactive Hypoglycemia Treated with a Low-dose Alpha-glucosidase Inhibitor: Voglibose May Suppress Oxidative Stress and Prevent Endothelial Dysfunction.
Topics: Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Inositol; Middle Aged; Oxidative Stress | 2016 |
Voglibose-inspired synthesis of new potent α-glucosidase inhibitors N-1,3-dihydroxypropylaminocyclitols.
Topics: alpha-Glucosidases; Animals; Binding Sites; Cyclitols; Gene Expression; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Intestines; Kinetics; Ligands; Molecular Docking Simulation; Protein Binding; Rats; Structural Homology, Protein; Structure-Activity Relationship; Sucrase | 2016 |
An in vivo invertebrate evaluation system for identifying substances that suppress sucrose-induced postprandial hyperglycemia.
Topics: Acarbose; Animals; Bombyx; Dietary Sucrose; Disease Models, Animal; Glucose; Glycoside Hydrolase Inhibitors; Hemolymph; Humans; Hyperglycemia; Inositol; Lactobacillales; Phylogeny; Postprandial Period | 2016 |
Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification.
Topics: Animals; Bile Acids and Salts; Body Weight; Eating; Gastrointestinal Tract; Hypoglycemic Agents; Inositol; Lipid Metabolism; Male; Metabolome; Mice; Mice, Inbred C57BL | 2016 |
Effects of Food Thickeners on the Inhibitory Effect of Voglibose Oral-disintegrating Tablets on Post-prandial Elevation of Blood Sugar Levels.
Topics: Administration, Oral; Adult; Blood Glucose; Chemical Phenomena; Female; Food Additives; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Postprandial Period; Solubility; Tablets | 2016 |
Online solid phase extraction and liquid chromatography-mass spectrometric determination of nucleoside drugs in plasma.
Topics: Chromatography, Liquid; Humans; Inositol; Metronidazole; Nucleosides; Online Systems; Solid Phase Extraction; Tandem Mass Spectrometry | 2016 |
Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Inositol | 2018 |
Impaired insulin/IGF-1 is responsible for diabetic gastroparesis by damaging myenteric cholinergic neurones and interstitial cells of Cajal.
Topics: Animals; Antigens, CD; Choline O-Acetyltransferase; Cholinergic Neurons; Diabetes Complications; Disease Models, Animal; Gastroparesis; Gene Expression Regulation; Humans; Inositol; Insulin; Insulin-Like Growth Factor I; Interstitial Cells of Cajal; Mice; Mice, Inbred NOD; Muscle, Smooth; Receptor, IGF Type 1; Receptor, Insulin; Stem Cell Factor | 2017 |
Nocturnal reactive hypoglycaemia well treated subjectively and objectively with voglibose.
Topics: Blood Glucose; Circadian Rhythm; Diagnosis, Differential; Female; Glucose Tolerance Test; Humans; Hypoglycemia; Hypoglycemic Agents; Inositol; Middle Aged | 2017 |
Rapid analysis of pharmaceutical drugs using LIBS coupled with multivariate analysis.
Topics: Air; Algorithms; Argon; Inositol; Lasers; Least-Squares Analysis; Linear Models; Multivariate Analysis; Pharmaceutical Preparations; Principal Component Analysis; Spectrum Analysis | 2018 |
Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Inositol; Linagliptin; Male; Middle Aged; Pilot Projects; Prognosis; Prospective Studies; Vasodilation | 2018 |
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
Topics: Aged; Autoantigens; Biopsy; Collagen Diseases; Collagen Type XVII; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Enzyme-Linked Immunosorbent Assay; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Non-Fibrillar Collagens; Pemphigoid, Bullous; Pyrazoles; Skin; Thiazolidines | 2018 |
Voglibose-mediated alterations in neurometabolomic profiles in the hypothalamus of high-fat diet-fed mice.
Topics: Amino Acids; Animals; Diet, High-Fat; Eating; Glycoside Hydrolase Inhibitors; Hypothalamus; Inositol; Male; Metabolome; Metabolomics; Mice, Inbred C57BL | 2019 |
Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hyperemia; Inositol; Magnetic Resonance Imaging; Male; Middle Aged; Sitagliptin Phosphate; Ventricular Function, Left | 2018 |
Interaction of antidiabetic α-glucosidase inhibitors and gut bacteria α-glucosidase.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Bacterial Proteins; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Models, Molecular; Protein Binding; Ruminococcus | 2018 |
Comparisons of Effects on Intestinal Short-Chain Fatty Acid Concentration after Exposure of Two Glycosidase Inhibitors in Mice.
Topics: Acarbose; Animals; Bacteroidaceae; Caco-2 Cells; Desulfovibrionaceae; Epithelial Cells; Fatty Acids, Volatile; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Humans; Inositol; Intestinal Mucosa; Intestines; Male; Mice; Mice, Inbred ICR; Starch | 2018 |
Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Apolipoprotein E2; Apolipoprotein E4; Carbonated Beverages; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diet, Fat-Restricted; Glycated Hemoglobin; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Inositol; Insulin; Ketosis; Male; Metformin; Obesity; Xanthomatosis | 2019 |
Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Insulin; Insulin Antibodies; Insulin Secretion; Isoindoles; Liraglutide; Male; Postprandial Period; Treatment Outcome | 2019 |
Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
Topics: Administration, Oral; Adult; Drug Compounding; Female; Humans; Inositol; Isoindoles; Male; Placebo Effect; Solubility; Tablets; Taste; Water; Young Adult | 2019 |
Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inositol; Metformin | 2019 |
Response: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inositol; Metformin | 2019 |
Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice.
Topics: Animals; Antioxidants; Azoxymethane; Biomarkers; Biopsy; Cell Proliferation; Colonic Neoplasms; Cytokines; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycoside Hydrolase Inhibitors; Humans; Inflammation Mediators; Inositol; Intestinal Mucosa; Mice; NF-kappa B; Obesity; Oxidative Stress; Precancerous Conditions | 2020 |
Role of Intestinal Microbiota in Metabolism of Voglibose In Vitro and In Vivo.
Topics: Animals; Diabetes Mellitus, Experimental; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Inositol; Mice | 2020 |
Promising Anti-stroke Signature of Voglibose: Investigation through In- Silico Molecular Docking and Virtual Screening in In-Vivo Animal Studies.
Topics: Animals; Cerebrovascular Disorders; Computer Simulation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hyperglycemia; Infarction, Middle Cerebral Artery; Inositol; Lipids; Molecular Docking Simulation; Neuroprotective Agents; Nitric Oxide; Rats; Risk Factors; Sodium-Potassium-Exchanging ATPase; Software; Stroke; User-Computer Interface | 2020 |
Pre-exposure of voglibose exerts cerebroprotective effects through attenuating activation of the polyol pathway and inflammation.
Topics: Animals; Hyperglycemia; Inflammation; Inositol; Male; Polymers; Rats | 2021 |
Spectroscopic and theoretical evidences for the surface binding of voglibose drug with DNA.
Topics: Circular Dichroism; DNA; Inositol; Molecular Docking Simulation; Pharmaceutical Preparations; Spectrometry, Fluorescence; Thermodynamics | 2022 |
The effects of the voglibose on non-alcoholic fatty liver disease in mice model.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Fructose; Glucose; Glycoside Hydrolase Inhibitors; Inositol; Lipogenesis; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pioglitazone | 2022 |
Voglibose Regulates the Secretion of GLP-1 Accompanied by Amelioration of Ileal Inflammatory Damage and Endoplasmic Reticulum Stress in Diabetic KKAy Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucose; Ileum; Inositol; Mice | 2022 |